Evaluation of comparative efficacy of Champakadi Agada versus Cetirizine in Sheetapitta (Recurrent Urticaria)-A reverse pharmacology approach.
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- 1. Champakadi Agada will demonstrate significant improvement in reducing Urticaria Activity Score (UAS), reduction in urticarial signs and symptoms compared to Cetrizine at the end of the 6-week treatment period.
研究概览
简要总结
Champakadi Agada, a traditional Indian herbal formulation, has been widely used to treat insect bites and various skin disorders. This natural remedy combines medicinal herbs with anti-inflammatory, antibacterial, and soothing properties. When applied, Champakadi Agada can effectively alleviate symptoms of skin allergies ,including redness, swelling, and itching.
This study explores the traditional use, processing, and potential health benefits of Champakadi Agada as a home remedy for skin allergies. Further research and clinical trials are necessary to validate its efficacy and potentially integrate it into broader dermatological treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged between 18-60 years
- •Patients diagnosed with Sheetapitta (recurrent Urticaria) as per Ayurvedic diagnostic criteria
- •Patients with mild to moderate Sheetapitta (Urticaria)
- •Patients with a history of Sheetapitta (Urticaria) for at least 6 weeks
- •Patients of Sheetapitta willing to give consent.
排除标准
- •Pregnant or lactating women
- •Patients with severe Sheetapitta (Urticaria) requiring hospitalization or emergency treatment
- •Patients taking medications that may interact with Champakadi Agad or Cetrizine, such as antihistamines, corticosteroids, or immunosuppressants
- •Patients with known allergies to Champakadi Agada ingredients or Cetrizine
- •Patients with chronic diseases such as diabetes, hypertension, or kidney disease.
结局指标
主要结局
1. Champakadi Agada will demonstrate significant improvement in reducing Urticaria Activity Score (UAS), reduction in urticarial signs and symptoms compared to Cetrizine at the end of the 6-week treatment period.
时间窗: 4-5 weeks, followup will be taken on 14 weeks, 30 weeks, 45th day of enrollment
2. The optimal dose of Champakadi Agada will be determined, with maximum efficacy at a specific dose and minimal adverse effects.
时间窗: 4-5 weeks, followup will be taken on 14 weeks, 30 weeks, 45th day of enrollment
次要结局
- 1. Champakadi Agad may show faster & more significant relief from symptoms such as itching, redness, & swelling compared to Cetrizine.(2. Champakadi Agada may found to be safe & well-tolerated, with fewer adverse effects compared to Cetrizine.)
研究者
Dr Priya Raut
Datta meghe ayurvedic medical college hospital and research centre wanadongri Hingana Nagpur.